CD274 and breast cancer: In addition, research on “immunotherapies,” like the PD-L1 monoclonal antibody pembrolizumab, has recently shifted from general breast cancer treatment to more specific therapies that target distinct subtypes of breast cancer, involving pembrolizumab for TNBC (Figure 6B).